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Malignant melanomas are aggressive tumors that are largely refractory to conventional drug therapies. A
recent study reported in Nature Genetics identified mutationally activated ErbB4 alleles in 20% of cases.
These tumor cells exhibit ErbB4 dependency, suggesting that ErbB4 kinase inhibition may constitute an
effective therapeutic strategy in this setting.Malignant melanomas are aggressive and
treatment-refractory cancers, associated
with a 5 year survival rate below 20%
(Chin et al., 2006). In other similarly chal-
lenging diseases, inhibitors of mutation-
ally activated kinases on which tumor
cells exhibit dependency have demon-
strated impressive clinical activity in
some patients. Such findings have pro-
mpted intensive efforts to resequence
the cancer ‘‘kinome’’ in various tumor
types to identify additional settings where
kinase inhibition might yield clinical
benefit (Stratton et al., 2009). One of the
most notable successes of such efforts
was the discovery of recurrent activating
alleles affecting the BRAF serine/threo-
nine kinase in 7% of all tumors examined,
including 65% of melanomas (Davies
et al., 2002). Consequently, BRAF kinase
inhibitors are undergoing clinical evalua-
tion, and preliminary findings suggest
that BRAF inhibition can yield good clin-
ical responses in the majority of mela-
noma patients harboring the recurrent
BRAF V600E allele (K. Flaherty, personal
communication). While these early find-
ings appear promising, alternative thera-
peutic strategies for malignant melanoma
will undoubtedly be needed.
In a recent issue of Nature Genetics,
Prickett and colleagues reported finding
somatic activating mutations of the ErbB4
receptor tyrosine kinase in 19% of ma-
lignant melanomas, revealing another
possible ‘‘Achilles’ heel’’ within these
tumors (Prickett et al., 2009). Sequencing
the kinase domain-encoding exons of all
86 predicted tyrosine kinases in 79 mela-
nomas revealed 19 genes in which muta-
tions were present, the vast majority of
which had not been previously implicated278 Cancer Cell 16, October 6, 2009 ª2009in melanoma. The ratio of nonsynony-
mous to synonymous mutations sug-
gested that most mutations corre-
sponded to oncogenic ‘‘drivers’’ as
opposed to coincidental ‘‘passengers.’’
Follow-up analysis was focused on
mutations in ErbB4, which were detected
in 15 of 79 melanoma samples (19%).
ErbB4 is one of four closely related mem-
bers of a family of growth factor receptors
that includes EGFR/ErbB1, HER2/ErbB2/
Neu, and HER3/ErbB3. Following ligand-
dependent receptor homo- or heterodi-
merization, these receptors transduce
kinase-mediated signals that modulate
cell proliferation, survival, and migra-
tion—processes that can directly impact
the malignant properties of cancer cells.
Indeed, each of the ErbB family receptors
has been implicated in human tumorigen-
esis. Thus, mutational activation of EGFR
is causally associated with many gliomas
and non-small cell lung cancers, and at
lower frequency in additional tumor types.
Activated HER2/ErbB2 directly contrib-
utes to 20% of breast cancers and
possibly some ovarian cancers and other
solid tumors. Both receptors can trans-
duce critical cell survival signals, via
heterodimerization with ErbB3, and en-
gagement of PI-3 kinase/AKT signaling.
Notably, a role for ErbB4 in cancer has,
until now, been less certain. In fact,
several studies have concluded that
ErbB4 may function as a tumor sup-
pressor in breast and prostate cancer
(Sundvall et al., 2008; Williams et al.,
2003), possibly by antagonizing ErbB2
signaling. However, this remains contro-
versial, as ErbB4 knockout mice do not
experience mammary tumorigenesis, and
ErbB4 disruption does not detectablyElsevier Inc.enhance the development of ErbB2-
driven mouse mammary tumors (Jack-
son-Fisher et al., 2006).
The findings by Prickett et al. are not
the first to report mutations of ErbB4 in
human cancer. Thus, an analysis of 595
tumors from stomach, lung, colon, and
breast revealed 12 cases with ErbB4
mutations (nine within coding sequences)
(Soung et al., 2006). Similarly, an analysis
of 188 lung adenocarcinomas revealed
9 cases with ErbB4 mutations; however,
these were not functionally validated
(Ding et al., 2008). Prickett and colleagues
examined the functional relevance of the
melanoma mutations, which were widely
scattered throughout the coding regions
of ErbB4, including the kinase and extra-
cellular ligand-binding domains. More-
over, only one of the 20 coding sequence
mutations detected (all missense muta-
tions) was observed more than once (it
was seen twice), in striking contrast to
the highly recurrent nature of activating
BRAF and EGFR mutations.
To validate their findings, these investi-
gators undertook functional studies of
seven of the ErbB4 melanoma mutants
to determine if they constitute activated
oncogenic alleles. In transfected cultured
cells, each of the mutant proteins
exhibited increased autophosphorylating
activity and increased transforming activ-
ity, as assessed in focus-forming and
anchorage-independent growth assays,
relative to wild-type ErbB4. Moreover,
they promoted elevated phospho-AKT.
Using RNA interference, they demon-
strated that ErbB4 ablation in cells ex-
pressing mutant alleles, but not in cells
expressingwild-typeErbB4, inhibitedpro-
liferation, and concluded that melanoma
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exhibit ErbB4 dependency, potentially
yielding a therapeutic opportunity.
To model the potential benefit of phar-
macologic ErbB4 inhibition, they treated
melanoma cell lines with lapatinib, a
pan-ErbB kinase inhibitor. Lapatinib is
approved for clinical use in trastuzumab
(Herceptin)-refractory breast cancers,
and demonstrates potent EGFR and
ErbB2 kinase inhibition. Although its
activity as an ErbB4 inhibitor is less well
characterized, Prickett et al. found that
ErbB4 mutant melanoma cell lines
were substantially more lapatinib-sensi-
tive than melanoma cells expressing
wild-type ErbB4. Notably, among a panel
of melanoma cells expressing various
ErbB4 mutants, a wide range of drug
sensitivity was observed, suggesting
either that the distinct ErbB4 mutants
display varying lapatinib sensitivities
or that additional differences between
these cell lines contribute to their drug
response. Moreover, the investigators
have not excluded a potential contributing
role for inhibition of EGFR and/or ErbB2—
both of which have been implicated in the
malignant properties of melanoma cells—
in lapatinib sensitivity. The development
of ErbB4-specific kinase inhibitors will
be required to definitively address this
issue.
The clinical implications of these find-
ings are potentially substantial. Lapatinib
is a clinically approved drug and could
be readily repurposed for use in ErbB4
mutant melanoma. Additional ErbB family
kinase inhibitors are currently undergoing
development, and some of these are also
likely to display ErbB4 inhibitory activity.
However, in light of the abovementioned
putative tumor suppressor function ofErbB4, systemic inhibition of this kinase
could be problematic, as it might actually
promote tumorigenesis in some tissues.
A curiosity that arises from these find-
ings is that activating ErbB4 and BRAF
mutations can be found in the same tumor
cells in some melanomas. Both kinases
can confer a state of ‘‘oncogene addic-
tion,’’ suggesting either that some mela-
noma cells can exhibit strict dependency
on two distinct signaling pathways or
that ErbB4 and BRAF participate in cross-
talk that effectively yields a single onco-
genic pathway with multiple vulnerabil-
ities.
The scattered nature of the identified
ErbB4 mutations throughout the coding
sequence is also curious, and further
studies will be needed to determine
whether all of these mutations lead to
kinase activation and/or increased sig-
naling and how these various mutations,
which affect distinct functional domains
of ErbB4, contribute to a similar degree
of elevated kinase and transforming
function. Interestingly, in one-third of the
melanomas found to harbor ErbB4 muta-
tions, more than one ErbB4 coding
sequence mutation was present within
the same sample, raising the possibility
that these mutations cooperate to
enhance ErbB4’s oncogenicity. The role
of these various mutations is further
confounded by a report demonstrating
that some of the previously detected
ErbB4 mutations in other tumor settings
confer loss of kinase activity while pre-
serving ErbB4’s ability to transduce
downstream signals via ErbB2, but with
a qualitatively distinct output (Tvorogov
et al., 2009).
Overall, these are provocative new find-
ings that reveal a potentially importantCancer Cell 1therapeutic opportunity for a challenging
disease. While clinical validation of these
observations will certainly be required,
this study opens up an exciting new
avenue of investigation in melanoma
research and highlights the increasingly
complex role of the ErbB family receptors
in cancer.
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